Difference between revisions of "Residual cancer burden index"
Jump to navigation
Jump to search
(Created page with "'''Residual cancer burden index''', abbreviated '''RCB''', is an empirical predictor of outcome in breast cancer in the post-neoadjuvant therapy setting.<ref>{{cite jo...") |
|||
| Line 1: | Line 1: | ||
'''Residual cancer burden index''', abbreviated '''RCB''', is an empirical predictor of outcome in [[breast cancer]] in the [[post-neoadjuvant therapy]] setting.<ref>{{cite journal |authors=Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JM, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF |title=Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients |journal=Lancet Oncol |volume=23 |issue=1 |pages=149–160 |date=January 2022 |pmid=34902335 |doi=10.1016/S1470-2045(21)00589-1 |url=}}</ref> | '''Residual cancer burden index''', abbreviated '''RCB''', is an empirical predictor of outcome in [[breast cancer]] in the [[post-neoadjuvant therapy]] setting.<ref>{{cite journal |authors=Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JM, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF |title=Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients |journal=Lancet Oncol |volume=23 |issue=1 |pages=149–160 |date=January 2022 |pmid=34902335 |doi=10.1016/S1470-2045(21)00589-1 |url=}}</ref> | ||
==See also== | |||
*[[Neoadjuvant therapy]]. | |||
==References== | ==References== | ||
Revision as of 23:26, 15 October 2024
Residual cancer burden index, abbreviated RCB, is an empirical predictor of outcome in breast cancer in the post-neoadjuvant therapy setting.[1]
See also
References
- ↑ Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JM, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF (January 2022). "Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients". Lancet Oncol 23 (1): 149–160. doi:10.1016/S1470-2045(21)00589-1. PMID 34902335.